DSP107

An Open-label Phase Ib Study of DSP107 for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
36 patients (estimated)
Sponsors
Kahr Medical
Tags
Antimetabolites, BCL-2 Inhibitor, Hypomethylating Agents (HMA), CD137, CD47
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1538
NCT Identifier
NCT04937166

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.